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Kinetoplastids are unicellular, eukaryotic, flagellated protozoans containing the
eponymous kinetoplast. Within this order, the family of trypanosomatids are responsible
for some of the most serious human diseases, including Chagas disease (Trypanosoma
cruzi), sleeping sickness (Trypanosoma brucei spp.), and leishmaniasis (Leishmania spp).
Although cAMP is produced during the life cycle stages of these parasites, its signaling
pathways are very different from those of mammals. The absence of G-protein-coupled
receptors, the presence of structurally different adenylyl cyclases, the paucity of known
cAMP effector proteins and the stringent need for regulation of cAMP in the small
kinetoplastid cells all suggest a significantly different biochemical pathway and likely
cell biology. However, each of the main kinetoplastid parasites express four class 1-
type cyclic nucleotide-specific phosphodiesterases (PDEA-D), which have highly similar
catalytic domains to that of human PDEs. To date, only TbrPDEB, expressed as two
slightly different isoforms TbrPDEB1 and B2, has been found to be essential when
ablated. Although the genomes contain reasonably well conserved genes for catalytic and
regulatory domains of protein kinase A, these have been shown to have varied structural
and functional roles in the different species. Recent discovery of a role of cAMP/AMP
metabolism in a quorum-sensing signaling pathway in T. brucei, and the identification
of downstream cAMP Response Proteins (CARPs) whose expression levels correlate
with sensitivity to PDE inhibitors, suggests a complex signaling cascade. The interplay
between the roles of these novel CARPs and the quorum-sensing signaling pathway on
cell division and differentiation makes for intriguing cell biology and a new paradigm in
cAMP signal transduction, as well as potential targets for trypanosomatid-specific cAMP
pathway-based therapeutics.
Keywords: Trypanosoma cruzi, Trypanosoma brucei, Leishmania, phosphodiesterase, cAMP, kinase, adenylyl
cyclase, PKA
Introduction
Trypanosomatids are protozoan parasites belonging to the order kinetoplastida, family
trypanosomatidae, and are characterized by a particular substructure of the mitochondrion, called
the kinetoplast, which contains the mitochondrial DNA. They are digenetic flagellated protozoans
with similar cellular structures as well as similar genome organization and are all known to undergo
morphological transformations during their life cycles (Stuart et al., 2008).Members of this order are
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unicellular eukaryotes, and many of them parasitize multicellular
organisms and cause medically and economically important
diseases in humans, their domestic animals and cash crops
(Barrett et al., 2003). Human African trypanosomiasis (HAT),
also known as African sleeping sickness, is a vector-borne
parasitic disease caused by the protozoan pathogen Trypanosoma
brucei and transmitted by several Glossina species, commonly
called tsetse flies (Stich et al., 2002). There are three sub-
species of T. brucei that infect mammals: Trypanosoma brucei
brucei, Trypanosoma brucei gambiense, and Trypanosoma brucei
rhodesiense. However, only T. b. gambiense (acute infections)
and T. b. rhodesiense (chronic infections) infect and cause
clinical disease in humans whilst T. b. brucei infect animals
causing the disease known as nagana in cattle (Fevre et al.,
2006; Brun et al., 2010). It has been estimated that the core
group of neglected tropical diseases (NTDs), the majority of
which are caused by trypanosomatids, results in the loss of more
than 57 million disability-adjusted life years (DALY), coupled
with attendant impacts on poverty (Hotez et al., 2006, 2009).
Although there has been dramatic improvement in infections
and death in recent years (Simarro et al., 2011), optimism is
tempered in the light of previous recurrences, migration and
the instability in many endemic regions (Odiit et al., 2005;
Picozzi et al., 2005; Mumba et al., 2011; Blum et al., 2012).
Although the old, toxic and difficult to administer drugs have
helped to combat the disease until the present (Delespaux and
de Koning, 2007; Kennedy, 2008; Barrett, 2010; Jacobs et al.,
2011), the current increase in resistance to these drugs is very
worrying (Vincent et al., 2010; Simarro et al., 2012; Baker et al.,
2013). If modern standards in pharmacology were to be applied,
the aforementioned issues with trypanosomatid chemotherapy
mean that there are effectively no acceptable chemotherapies for
these diseases. A quest to produce more clinically effective and
less toxic drugs is hampered by the fact that, as eukaryotes,
trypanosomatids are genetically and evolutionarily much closer
to their human hosts than bacteria, resulting in problems with
selectivity and toxicity (Seebeck et al., 2011). In the context of
cAMP metabolism, the kinetoplastid phosphodiesterases (PDEs)
are highly similar to that of most of the well-studied human
homologs. However, PDEs are highly amenable to selective
inhibition, due to small differences in their binding pockets that
can be exploited by structure-based inhibitor design, even when
using the pharmacologically well explored scaffolds of human
PDE inhibitors. Moreover, downstream effectors of cAMP are
very different in human and trypanosomatid cells, potentially
providing further drug targets, this time without mammalian
counterparts.
Signal Transduction in Trypanosomatids
Adenylate Cyclases
Signal cascades exist for the amplification of a small signal into
a large response, leading to significant cellular changes such
as expression of specific genes, the activity of certain proteins,
or changes in cell cycle progression. Many disease processes,
such as diabetes, heart disease, autoimmunity and cancer, arise
fromdefects in signal transduction pathways, further highlighting
the critical importance of signal transduction to biology as well
as the development of medicine (Huang et al., 2010). Cyclic
AMP levels in most eukaryotes are increased by stimulation of
adenylyl cyclases (ACs), whilst cyclic nucleotide PDEs degrade
the phosphodiester bond in cAMP, thereby limiting or abrogating
signal transduction. A putative kinetoplastid AC gene was first
identified in T. brucei when the active gene expression site of
a variant surface glycoprotein (VSG) was sequenced, revealing
that there were multiple genes in the site that were co-expressed
with VSG. These genes were termed expression site-associated
genes (ESAGs), and one of them, ESAG4, showed homology with
an AC from yeast (Pays et al., 1989). Further copies of apparent
ACs were identified in the genome and named GRESAG4.1 and
GRESAG4.2 (genes related to ESAG4; Pays et al., 1989). Related
genes were also found inT. b. gambiense,Trypanosoma congolense,
Trypanosoma mega, Trypanosoma equiperdum, and Trypanosoma
vivax. These apparent AC genes were proven to actually code
for functional AC enzymes by complementing AC-deficient yeast
mutants (Ross et al., 1991; Paindavoine et al., 1992).
Since then similar multigene families with high homology to
ESAG4 and GRESAG4.1 have also been identified in Leishmania
donovani and T. cruzi, and these ACs share the same predicted
protein architecture (Sanchez et al., 1995). T. brucei encodes
up to 20 telomeric ESAG4 AC genes and approximately 65
GRESAG4 proteins (Salmon et al., 2012a,b) and at least some of
these are localized along the flagellum both in the mammalian-
infective bloodstream forms (BSFs) and in procyclic (fly midgut
stage) cells (Paindavoine et al., 1992; Saada et al., 2014). Their
similarity results in cross-reactivity with some antibodies raised
against ESAG4 (Paindavoine et al., 1992; Oberholzer et al., 2011).
Whereas knocking out ESAG4 from the expression site does not
affect parasite proliferation, a knockdown of all the AC family
that includes ESAG4 and the two GRESAG4 genes led to a total
decrease in AC activity, resulting in a phenotype that is defective
in cytokinesis (Salmon et al., 2012a).
Trypanosomatid ACs contain a single trans-membrane
domain, a conserved intracellular C-terminal domain, and a
large variable extracellular domain. The N-terminal domains
may function as receptors, similar to mammalian receptor-type
guanylyl cyclases (Garbers et al., 2006). Whilst the catalytic
domain is structurally very similar to those of mammalian
ACs, it is not activated by forskolin. The purified proteins form
homodimers in vitro (Bieger and Essen, 2001; Naula et al., 2001;
Gould and de Koning, 2011) and dimerization was recently
also shown in vivo (Saada et al., 2014). The possibility of the
N-terminal extracellular domain of ACs acting as a receptor for
signaling due to the lack ofG-protein-coupled receptor (GPCR) in
the kinetoplastid genome has been strongly speculated (Seebeck
et al., 2004; Laxman and Beavo, 2007). Indeed, the recently
revealed relationship of the N-terminal of a representative AC
from T. brucei with an Escherichia coli L-leucine-binding protein
(LBP; Emes and Yang, 2008) and a similar LBP that acts as an
amide receptor in Pseudomonas aeruginosa (O’Hara et al., 2000)
have lend support to the hypothesis that AC activity could be
directly regulated by extracellular stimuli. Analysis of the AC
gene clusters also showed that the variation in the extracellular
domains, specifically in areas predicted to come into close
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contact with putative ligands, appear to be significantly driven by
positive selection. This is an indicator of adaptive evolution and
consistent with a receptor or sensory function for at least some
of the cyclases (Emes and Yang, 2008). Although no putative
ligand has been identified as yet, some extracts from T. cruzi
and T. brucei insect vectors have been shown to activate ACs,
whilst a low-molecular-weight molecule, stumpy induction factor
(SIF), probably secreted by the trypanosome itself, was inferred to
trigger the differentiation of long slender bloodstream T. brucei to
the non-replicating stumpy form via the cAMP signaling cascade
(Garcia et al., 1995; van den Abbeele et al., 1995; Vassella et al.,
1997). In addition it has been shown that ACs influence host
parasite interactions through the modulation of tumor necrosis
factor alpha (TNF-) and that AC activity of lysed trypanosomes
contributes to establishing an infection of these parasites in a host
(Salmon et al., 2012b).
The above suggests that diversity in ACs provides an adaptive
advantage to the extracellular T. brucei enabling host immune
evasion and modulation, and thus survival. It is postulated that
the high number of ACs of T. brucei species, compared with
the intracellular T. cruzi and Leishmania, has to do with the
evasion of the host immune system by continuously switching its
VSG expression in the various telomeric sites, which resulted in
the duplication of ESAGs, including ACs (ESAG4). Other forces
of selection may then have resulted in alternative specificities
for the individual receptor-cyclases to arise. Thus, the large
numbers of ACs found in the T. brucei genome may allow more
specific responses to the multiple ligands found in its extracellular
environment, compared with the relatively sheltered intracellular
lifestyle of Leishmania and T. cruzi (Gould and de Koning, 2011).
The cellular localization of the ACs of kinetoplastids is also
consistent with them acting as a receptor. Antibodies against
ESAG4were shown to specifically bind to the cell surface along the
flagellum in both BSFs and procyclic trypanosomes (Paindavoine
et al., 1992). Similarly, in T. cruzi epimastigotes, the calcium-
stimulatable AC was found to be associated with the flagellum
(D’Angelo et al., 2002).
Proteomic analysis of bloodstream T. brucei flagella and plasma
membrane fractions have identified receptor and transport-like
proteins that likely play important roles in signaling and parasite-
host interactions (Bridges et al., 2008; Oberholzer et al., 2011).
Recently, several receptor-type flagellar ACs have been shown
to be specifically expressed in the procyclic stage, glycosylated,
surface-exposed and catalytically active. Interestingly, these
cyclases were differentially distributed: either along the entire
flagellum or localized to just the tip of the flagellum (Saada
et al., 2014). This indicates a microdomain flagellar cyclic
AMP signaling in T. brucei, and that ACs have specific
subdomains. These possibilities were further strengthened by the
findings that one of these insect stage specific ACs (adenylate
cyclase 6) is responsible for social motility and that functional
mutation or RNAi knock-down results in a hypersocial phenotype
(Lopez et al., 2015), again demonstrating the involvement of
cAMP signaling in response to extracellular stimuli. All these
observations together, coupled with the fact that cAMP levels
are significantly increased during the differentiation of T. brucei
BSFs to procyclic forms (Vassella et al., 1997), suggests a probable
role of cAMP involvement in parasite behavior and differentiation
through ACs.
Similarly, T. cruzi ACs form dimers (D’Angelo et al., 2002) and
have been implicated in the conversion of epimastigotes in the
insect midgut, and later in the hindgut, into human-infectious
non-proliferative metacyclic trypomastigotes (Gonzales-
Perdomo et al., 1988; Fraidenraich et al., 1993; Garcia et al., 1995),
a process known as metacyclogenesis that is akin to cellular
differentiation of BSF T. brucei to procyclic forms. This event
can reportedly be triggered in vitro by a proteolytic fragment
of -D-globin from the insect host’s hindgut (Fraidenraich
et al., 1993), confirming a role for cAMP in mediating parasite
responses to environmental changes. In vitro metacyclogenesis
triggered by nutritional stress also caused an increase in cAMP
production (and cellular content) in two phases (Hamedi et al.,
2015), with a first peak rapidly following the initiation of
differentiation, and a second phase of elevated cAMP associated
with the adhesion of the epimastigotes that is a prerequisite for
their final differentiation to metacyclic trypomastigotes (Boker
and Schaub, 1984).
Protein Kinase A
The cAMP-dependent protein kinase (PK) family or protein
kinase A (PKA) is a collection of serine/threonine kinases whose
activity is dependent on levels of cAMP in the cell and is one
of the most studied and best known members of the PK family
(Huang, 2011). The kinetoplastid genomes contain reasonably
well conserved genes for catalytic and regulatory domains of
PKA (Huang et al., 2006). In T. brucei, a 499-amino acid
protein with high homology to eukaryotic regulatory subunits
of PKA was identified and named TbRSU. This led to the first
actual measurement of the cyclic nucleotide-dependent kinase
activity in T. brucei. The protein has the usual two cyclic
nucleotide-binding domains, which are predicted to retain all the
conserved residues necessary for function, as well as a pseudo-
inhibitor site, which interacts with the catalytic subunit (Shalaby
et al., 2001). However, further research on the kinase activity
co-immunoprecipitated with TbRSU showed that although it
displayed phosphorylation activity and was also inhibited by the
protein kinase inhibitor peptide (PKI), both characteristics of
PKA, it was not stimulated by cAMP but was instead stimulated
by cyclic guanosine monophosphate (cGMP; Shalaby et al., 2001).
There is to date scant evidence of cGMP production in any of
the kinetoplastid parasites, although a soluble, cytosolic guanylate
cyclase activity was described in L. donovani (Karmakar et al.,
2006), andMacLeod et al. (2008) reported that feeding cGMP (but
not cAMP) to tsetse flies resulted in higher trypanosome infection
rates.
The finding that cAMP signaling mediates T. cruzi
differentiation (Flawia et al., 1997) and the fact that PKAs
are the major effectors in most eukaryotic cells, led to the need
to identify PKA activity in T. cruzi. A cAMP-stimulatable PK
fraction was identified and displayed a half-maximal effect at
approximately 1 nM cAMP. As expected for a cAMP-dependent
kinase its activity was not affected by cGMP; moreover, its
phosphate-acceptor profile (including histones and kemptide,
but not casein and phosvitin) was consistent with other PKA
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activities (Ulloa et al., 1988). The holoenzyme appeared to consist
of two regulatory and two catalytic subunits (Ochatt et al., 1993).
Expression of both the T. cruzi PKA catalytic subunit (TcPKAc)
and the T. cruzi PKA regulatory subunit (TcPKAr) is similarly
regulated and leads to coordinated expression in the life cycle
stages, indicating that the two subunits are associated in vivo, as
also shown by immunoprecipitation of the holoenzyme (Huang
et al., 2002; Huang, 2011). TcPKAc activity was inhibited by
the PKA-specific inhibitor PKI and both TcPKAc and TcPKAr
localized to the plasma membrane and the flagellar region
(Huang et al., 2002, 2006; Bao et al., 2010). TcPKAr was found to
interact with several P-type ATPases, which suggests that these
P-type ATPases may play a role in anchoring PKA to the plasma
membrane and could play a role in compartmentalization of the
kinase (Bao et al., 2009), as reported for some mammalian P-type
ATPases (Xie and Cai, 2003).
The functional importance of the TcPKAc in T. cruzi was
examined by introducing a gene encoding a PKI peptide
containing a specific PKA pseudo-substrate, Arg-Arg-Asn-Ala,
into epimastigotes. Expression of this PKI has a lethal effect on
the parasite. Similarly, a pharmacological inhibitor, H89, killed
epimastigotes at a concentration of 10 mM proving that PKA
enzymatic activity is essential for the survival of the parasites
(Bao et al., 2008). A yeast two hybrid screen for the substrates
of PKA identified 38 candidate proteins that interact with
TcPKAc, including eight genes with potential regulatory functions
with respect to environmental adaptation and differentiation.
These included a type III PI3 kinase (Vps34), a putative PI3
kinase, a MAPK, a cAMP-specific phosphodiesterase (PDEC2),
a hexokinase, a putative ATPase, a DNA excision repair protein
and an aquaporin. PKA phosphorylated the recombinant proteins
of these genes (Bao et al., 2008). Additional findings also suggest
TcPKAc may play a role in invading cells by mediating protein
trafficking that enables parasite adhesion to cells, enabling the
invasion thereof, as trans-sialidases were found to be substrates
of TcPKA (Bao et al., 2010). As discussed by Huang (2011), there
seems to be co-incidence of cAMP production, PKA activity and
trans-sialidase expression enabling the differentiation from late
stage epimastigotes to invasive trypomastigotes—all consistent
with a role for cAMP signaling in differentiation and invasion by
T. cruzi.
A Leishmania catalytic subunit of PKA (LdPKA) was first
isolated and characterized from L. donovani promastigotes by
column chromatography and found to be similarly inhibited
by PKI as in T. brucei and T. cruzi, indicating that the
kinetoplastid enzymes are likely to be structurally related, as well
as topologically similar to mammalian PKA. Indeed, LdPKAc
was able to make a functional holoenzyme when combined
with the regulatory subunit of a mammalian cAMP-dependent
kinase (Banerjee and Sarkar, 1992). In Leishmania major, a
gene encoding a protein with high homology to other PKA
catalytic subunits (LmPKA-C1) was cloned. Analysis of the
sequence and structural modeling showed the protein to have
all the conserved domains of eukaryotic PKAs involved in ATP
and substrate binding. However, some structural and functional
differences were observed with other PKA-C subunits, such
as a unique 8-residue C-terminal extension (Siman-Tov et al.,
1996, 2002). Expression of LmPKA-C1 was developmentally
regulated with expression barely detectable in intracellular
amastigotes, in contrast to a high expression level in insect-
stage promastigotes (Siman-Tov et al., 1996; Duncan et al.,
2001).
The role of cyclic nucleotide-regulated PK activities in
promastigote proliferation and infectivity was confirmed in
Leishmania amazonensis, with PKA activity particularly high
in metacyclic promastigotes, which are primed for macrophage
invasion (Genestra et al., 2004). PKA inhibitors PKI and H89
affected both replication and macrophage infection. Smaller
effects were observed with the PDE inhibitors dipyridamole,
rolipram and isobutyl-methyl-xanthine (IBMX) but to date we
are not aware of confirmation that these effects were mediated
by one of the leishmanial PDEs, or which one. These effects were
temporary and did not affect intra-macrophage growth (Malki-
Feldman and Jaffe, 2009).
Phosphodiesterases
It is long been self-evident that increased knowledge of cyclic
nucleotide signaling pathways can lead to the development
of therapeutic agents against human diseases (Maurice et al.,
2014). General pharmacological principles particularly support
the potential of PDEs as therapeutic targets, as regulating the
degradation of a second messenger or ligand offers a more
effective intervention in cellular levels than through regulation of
the rate of synthesis.Moreover, endogenous levels of the substrates
(cAMP and cGMP) are not very high within the cells (between
submicromolar and at most 10 mM) and competitive inhibitors
can therefore be much more effective than against, for instance,
PKs, where inhibitors must compete against millimolar levels of
ATP (Bender and Beavo, 2006).
Inmammals, PDEs exist as a superfamily and are classified into
11 families on the basis of their sequence identity, biochemical and
pharmacological properties, regulation, and substrate specificity
(Maurice et al., 2014). PDEs have their well-conserved catalytic
domain located near their C-terminus and may contain various
regulatory domains at the N-terminal end (Laxman and Beavo,
2007; Shakur et al., 2011) which presents extensive variations
(Gancedo, 2013). PDEs may contain allosteric cyclic nucleotide
binding sites in addition to their catalytic sites.
Phosphodiesterases have been grouped into three classes based
on their different catalytic domains. Class I PDEs are found in
all eukaryotes and they are the only forms of PDEs in higher
eukaryotes (Beavo, 1995). Class I PDEs are the only enzymes
that are capable of efficiently hydrolysing cyclic nucleotides. The
genome of known kinetoplastids encodes four different class I
PDEs (PDE-A to PDE-D) and does not contain members of
the other PDE classes (Beavo, 1995) just as is the case in the
human genome (Seebeck et al., 2011). At least one copy of each
of the four PDE genes is present in the genome database of T.
brucei, T. cruzi, and L. major (Vij et al., 2014). Class II PDEs
are found in certain prokaryotes (e.g., Vibrio fischeri) or fungi
(e.g., Saccharomyces, Candida) and in many lower eukaryotes
(e.g., Dictyostelium discoideum). These PDEs also catalyze the
hydrolysis of phosphodiester bonds but they do not show the same
substrate selectivity as the class I enzymes (Bender and Beavo,
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FIGURE 1 | Non-rooted tree of Class I protozoan and human PDEs. The
catalytic domains of many protozoan PDEs, including T. brucei (in red), are as
closely related to the human PDEs (in blue) as these are among themselves.
Hs, Homo sapiens; Pf, Plasmodium falciparum; Ca, Candida albicans; Tp,
Theileria parva; Gl, Giardia lamblia; Ch, Chilomastix hominis; Ec,
Encephalitozoon cuniculi; Dd, Dictyostelium discoideum. Figure courtesy of
Professor T. Seebeck, University of Bern, Switzerland.
2006). Class III PDEs are restricted to the bacteria (Gancedo,
2013).
Phosphodiesterases are regulated at multiple levels
and by a number of factors, such as at the genetic level
(transcriptional control), through biochemical mechanisms (e.g.,
phosphorylation and dephosphorylation), binding of Ca2+,
various protein–protein interactions, and by binding of cAMP
or cGMP to allosteric sites (Bender and Beavo, 2006). The field
of PDE research has greatly advanced and moved from basic
identification of PDE enzymes and characterization of their
kinetic and regulatory properties to more recent work on their
structure and activity regulation. Major efforts, and important
successes, are ongoing in the pharmacological exploitation
of human PDEs (Azam and Tripuraneni, 2014; Chen et al.,
2015; Fallah, 2015). In contrast, after 30 years of work in the
area of cAMP signaling and its role in the cell biology and
virulence of kinetoplastids, many of the fundamental questions
remain unanswered. Shakur et al. (2011) argue that the implicit
assumption that cAMP signaling in kinetoplastids would
be organized as in mammals substantially delayed progress.
Although this assumption has proven to be far from true, the
catalytic domains of trypanosomatid PDEs, at least, are as highly
conserved in relation to their human homologs as the 11 human
PDEs are among themselves and similarly are suitable targets for
drug screening and development (Seebeck et al., 2011; Shakur
et al., 2011).
The kinetoplastid genomes all code for the same set of cyclic
nucleotide-specific class 1-type PDEs with catalytic domains
that are highly similar to those of the human PDEs (Figure 1;
Beavo, 1995; Kunz et al., 2006). PDEs are hydrolases that convert
cAMP or cGMP into the corresponding 50-monophosphates
(50-AMP and 50-GMP; Alonso et al., 2006). This makes them
important players in signaling pathways as they regulate the
(rate of) degradation of these cyclic nucleotides, and are
thus an important factor in determining cyclic nucleotide
concentrations at the cellular and subcellular levels (Bender
and Beavo, 2006). Through their own cellular distribution
PDEs can be instrumental in directing or containing a cyclic
nucleotide signal in a particular location, thereby preventing its
diffusion throughout the cell (Johner et al., 2006; Maurice et al.,
2014).
Although protozoan PDEs are valid targets for the development
of antiparasitic drugs, one must not ignore the potential of side-
effects arising from inhibition of human PDEs. Early work, testing
mammalian PDE inhibitors against kinetoplastid PDEs was
encouraging in that these displayed no significant activity against
the parasite enzymes (Johner et al., 2006; Laxman et al., 2006; de
Koning et al., 2012), suggesting that they are pharmacologically
distinct frommammalian PDEs and that structure-assisted design
of selective inhibitors should be possible, just as it has been for
single human PDEs. Although the fine-tuning of an inhibitor to
a single therapeutic target could aid in the development of drug
resistance by single point mutations in the target enzyme, this is
an unfortunate reality in all target-based drug design (Seebeck
et al., 2011). However, as the inhibitors are targeted to the active
site of essential enzymes (protozoan PDEs), mutations that also
reduce substrate binding or catalytic activity would be lethal to
the parasites. In vitro induction of resistance to the PDE inhibitor
CpdA in T. brucei did not result in PDE mutations (Gould et al.,
2013).
In T. brucei, PDEA is a single-copy gene; apart from the Class
I active domain it shows almost no similarity to the mammalian
PDEs, placing it in a separate gene family, and appears to be
expressed throughout the life cycle (Kunz et al., 2004). It has
been characterized but does not appear to be essential for BSFs
of T. brucei, as genetic deletion mutants were viable and did not
display reduced proliferation rates in vitro (Gong et al., 2001; Kunz
et al., 2004). TbrPDEB, on the other hand, exists as a small family
of genes that are much more closely related to the mammalian
PDEs. The TbrPDEB family was the first kinetoplastid PDE to be
cloned and characterized. Based on inhibitor studies, TbrPDEB1
was believed to be an essential protein for the proliferation of
the African trypanosomiasis parasite and regulation of cyclic
nucleotide levels (Zoraghi and Seebeck, 2002). However, the
parasite expresses two closely related PDEBalleles, TbrPDEB1 and
TbrPDEB2, which can compensate for each other; knockdown
by RNAi of both alleles together leads to severe cell cycle defects
and cell death, both in vitro and in vivo (Oberholzer et al., 2007).
Interestingly, the two isoforms have somewhat different cellular
localizations.Whereas, TbrPDEB1 is located only in the flagellum,
TbrPDEB2 additionally localizes to the cytoplasm (Oberholzer
et al., 2007). As knockdown of TbrPDEB2 alone does not affect
cellular viability it must be the loss of flagellar PDE activity that is
critical.
More recently, a tetrahydrophthalazinone compound named
CpdA, a highly potent inhibitor of both TbrPDEB isoforms, was
shown to display similarly potent activity against the parasites in
vitro. The inhibitor was discovered from a screen of more than
400,000 compounds and displayed an IC50 value below 10 nM
against TbrPDEB1, with similar activity on TbrPDEB2, and a
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mid-nanomolar effect on trypanosome viability (de Koning et al.,
2012). Independent pharmacological validation of the TbrPDEB
isoforms was also reported by Bland et al. (2011) using the hPDE4
inhibitor piclamilast and a number of analogs. As CpdA was also
known to be a potent inhibitor of humanPDE4 (VanderMey et al.,
2001a,b), it is clear that the TbrPDEB family is pharmacologically
closest to this human PDE. In contrast, human PDE5 inhibitors
including sildenafil and tadalafil analogs displayed only weak
inhibition of TbrPDEB1 (Ochiana et al., 2012;Wang et al., 2012a).
Validation of the pharmacological importance of TbrPDEB1 was
further confirmed when homologymodeling and docking studies
were used to guide fragments of Catechol Pyrazolinones into
the parasite pocket (P-pocket) of TbrPDEB1 resulting in a new
series of compounds with nanomolar EC50 values against the
enzyme while also displaying promising trypanocidal activity
and stimulating cellular cAMP levels (Orrling et al., 2012). The
presence of the P-pocket in the otherwise highly conserved cAMP
binding site was first reported for L. major PDEB1 (Wang et al.,
2007) but present in all members of the kinetoplastid PDEB family
examined to date, including TbrPDEB1 (Jansen et al., 2013), as
well as TcrPDEC (Wang et al., 2012b). This is obviously very
important since it allows for the development of kinetoplastid-
specific PDE inhibitors with minimal or no cross reactivity with
mammalian PDEs, which lack this pocket (Figure 2).
In T. cruzi, TcrPDEB1 was located in membrane fractions of
the parasite and confocal microscopy showed it to be strongly
associatedwith the flagellum (D’Angelo et al., 2004). The very high
level of homology between kinetoplastid PDEB genes, and the
conserved duplication into a B1 and B2 allele in tandem, appear
to indicate that these genes play a crucial regulatory function in
the cells. All kinetoplastid PDEB family members contain two
N-terminal cAMP-binding GAF regulatory domains and a C-
terminal catalytic domain (Laxman et al., 2005; Diaz-Benjumea
et al., 2006; Johner et al., 2006; Shakur et al., 2011), but none of
the other kinetoplastid PDE families do (Figure 3). Of these PDE
families, the PhosphodiesteraseD (PDEDs) have as yet barely been
explored beyond the mere presence of the homologous genes in
the respective genomes.
As at least some of the trypanosomatid PDEs have been shown
to be essential regulatory enzymes, there is now much interest in
these enzymes as drug targets and substantial efforts are ongoing,
ranging from high-throughput screening, to structure-based
design, compound repurposing and fragment-based inhibitor
design (de Koning et al., 2012; Amata et al., 2014, 2015; Blaazer
et al., 2015). As discussed extensively by Seebeck et al. (2011),
this strategy has many advantages to drug development for the
highlyNTDs caused by kinetoplastid parasites, exactly because the
target is highly conserved with closely related human homologs.
First of all the interest in human PDEs by Big Pharma has
resulted in large compound libraries of potential inhibitors.
Furthermore, the potential side-effects and toxicity issues of
inhibiting any of the human PDEs have been well investigated,
as have the stability and pharmacokinetic properties of most
of the inhibitor scaffolds. Most crucially, it has proven to be
relatively straightforward to engage with the pharmaceutical
industry on inhibitors for kinetoplastid PDEs, as they already
have similar programs for other diseases. This strategy has
allowed the rapid identification of potent inhibitors of TbrPDEB
and other kinetoplastid PDEs but needs to rely on relatively
small differences in the binding pocket, notably the P-pocket
(Figure 2) of the enzyme, to achieve selectivity over human
PDEs.
The Role of cAMP Signaling in T. brucei
The presence of cAMP in trypanosomes, and its variation during
the course of infection, were recognized early on (Strickler and
Patton, 1975). However, the completion of various kinetoplastid
genome projects has revealed that cAMP signaling in the
kinetoplastids is starkly different from the pathways so extensively
studied in higher eukaryotes. Some important differences include
the fact that kinetoplastid genomes do not code for G-protein-
coupled receptors, or for heterotrimeric G proteins or PK G.
Furthermore, the ACs are structurally very different from their
mammalian counterparts, although the basic catalyticmechanism
seems to be conserved between them, and may have assumed
the role of receptors. Finally, apart from apparent PKA subunits
in T. cruzi (Huang et al., 2006) and L. donovani (Bhattacharya
et al., 2012), no homologous genes for cAMP effectors were
identified in these genomes. The regulatory subunit of T. brucei
PKA does not appear to bind cAMP, but instead binds cGMP
(Shalaby et al., 2001), although, as discussed above, there is no
convincing evidence that cGMP is produced by these parasites.
Thus, it is likely that PKA is not activated by cyclic nucleotides in
T. brucei.
The need for parasite survival implicates the need for a
developmental response to adapt to different environments
encountered within the mammalian host and throughout the
arthropod vector. This is especially so during preparation
for transmission, where specialized developmental forms
are often generated to promote survival when ingested or
propagated by a biting insect (Baker, 2010; MacGregor et al.,
2012). The result is a dynamic balance of transmissible and
proliferative stages within a host, ensuring that the population
can maximize its longevity within the host but also optimize
its capacity for spread to new hosts (Mony et al., 2014). The
morphotypes that characterize a certain genus are cell shape,
dimensions and the positions of the kinetoplast-flagellar
pocket relative to the nucleus (Svobodova et al., 2007). These
complex morphological and biochemical changes during cell
differentiation in trypanosomatids are environmentally driven
through different ligands and/or stimulatory molecules present
in these environments, most of which are yet to be identified
(Parsons and Ruben, 2000).
The report of AC activity in T. b. gambiense in 1974
(Walter et al., 1974) implicated the possible role of cAMP
signaling in the cell biology and virulence of kinetoplastids,
triggering the study of cAMP levels in the different life cycle
stages of Trypanosoma lewisi (Strickler and Patton, 1975),
T. b. brucei (Mancini and Patton, 1981), and L. donovani
(Walter et al., 1978). Trypanosomes living in the bloodstream
proliferate as morphologically “slender” forms that evade host
immunity by antigenic variation, generating characteristic waves
of infection. As each wave of parasitaemia ascends, slender
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FIGURE 2 | Model of the binding pocket of TbrPDEB1 and hPDE4. Model of the superimposed binding pockets of TbrPDEB1 (turquoise ribbons and
carbon atoms) and hPDE4B (orange ribbons, gray carbon atoms). The figure depicts chain A from the published 4I15 PDEB1 structure and chain B of hPDEB
structure 1XM4 (alignment RMSD 1.847 Angstrom). (A) Ribbon model of the cAMP binding pocket. (B) Same view but with the molecular surface for
TbrPDEB1 residues shown. Side chains for the conserved hydrophobic clamp phenylalanine residue in TbrPDEB1 (Phe877, turquoise) and hPDE4B (Phe446,
gray carbons) are shown to illustrate the orientation of the P pocket relative to this canonical binding site feature. Side chains for the pair of amino acid
residues at the entrance to the P pocket in TbrPDEB1 and hPDE4B are also shown—Met861 and Gly873 in TbrPDEB1 (turquoise), and Met431 and Ser442 in
hPDE4B (colored by element—carbon gray, hydrogen white, nitrogen blue, oxygen red, sulfur yellow). For TbrPDEB1 the P-pocket is clearly visible in Frame B,
directly adjacent to the main ligand binding site and delineated by M861 and G873, where in hPDE4B this space is filled entirely by M431 and S442. The
models were constructed by Dr. R. K. Campbell of the Marine Biology Laboratory, Woods Hole, MA, USA, using Maestro software release 2015-2
(Schrödinger, Portland, OR, USA).
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FIGURE 3 | Diagram of the domain structure of the kinetoplastid PDEs.
The conserved catalytic domain is the main functional domain of the PDEs
and binds cAMP. The GAF-A domains of PDEB1 and B2 bind cAMP and
cGMP and regulate the function of the catalytic domain (Laxman et al., 2005).
FYVE finger has been shown to bind two Zn2+ ions. Coiled-coil domains are
important in stabilizing protein structure and thus for protein function.
Phosphorylation of the indicated serine residues of PDEB1 has been
observed in the T. brucei phosphoproteome (Nett et al., 2009) whilst a
probably functionally conserved PKA phosphorylation site is predicted in
PDEB1/B2 (Shakur et al., 2011).
forms stop proliferating and undergo transformation to stumpy
forms, the parasite’s adaptation for transmission to the tsetse
fly vector (Vickerman, 1985). Earlier cAMP measurements
showed increased cAMP levels in long slender BSFs during the
cyclical wave of proliferation of these cells, and relatively low
cellular cAMP concentrations when the abundance of stumpy
forms increases (Mancini and Patton, 1981). The differentiation
of longer slender forms to short stumpy forms has been
shown to be density dependent (Vassella et al., 1997) with
resemblance to quorum-sensing systems found in microbial
communities (Waters and Bassler, 2005). The response to this
density-dependent differentiation is triggered by a yet to be
identified low molecular weight molecule called SIF, and it
has been speculated that this triggers a cAMP response as the
cAMP analog 8-(4-chlorophenylthio)-cAMP (8-pCPT-cAMP)
was demonstrated to have the same differentiation-inducing
effect as SIF. Additionally, trypanosomes incubated with a
conditioned medium containing SIF displayed a twofold to
threefold increase in the intracellular concentration of cAMP
compared with cells grown in a non-conditioned medium
(Vassella et al., 1997; Breidbach et al., 2002). Moreover, there had
been a tentative link between cAMP signaling and differentiation
of the BSFs to the insect procyclic forms, a process that is
accompanied by the shedding of its VSG surface coat (Barry
and McCulloch, 2001). However, monitoring of AC activity
and VSG shedding after triggering differentiation to procyclic
forms showed that AC stimulation was not responsible for
the release of VSG (Rolin et al., 1993), and cAMP was not
required for differentiation to occur (Strickler and Patton, 1975;
Mancini and Patton, 1981). High concentrations of extracellular
cAMP, 50-AMP or adenosine did not significantly affect the
proliferation of T. brucei, suggesting that the antiproliferative
effect caused by the nucleotide analogs was mediated by
an intracellular “receptor.” And although 8-pCPT-cAMP did
induce differentiation into stumpy-like non-proliferative forms,
a hydrolysis-resistant analog did not, whereas the hydrolysis
products of 8-pCPT-cAMP (i.e., the equivalent AMP and
adenosine analogs) had a more potent effect than 8-pCPT-cAMP
itself (Laxman et al., 2006). The clear conclusions of this
study were that (1) cAMP is not the primary effector of the
differentiation signal and (2) the hydrolysis products of 8-pCPT-
cAMP trigger a differentiation-like transformation in T. brucei
long-slender BSFs.
This insight was used to good effect when a genome-wide
RNAi target sequencing (RITseq) approach was used to identify
signaling components driving stumpy formation by exposing
and selecting proliferative monomorphic cell lines unresponsive
to 8-pCPT-cAMP or 8-pCPT-2-O-methyl-5-AMP-driven stumpy
formation. This led to the identification of a cohort of genes
implicated in each step of the signaling pathway, from genes
involved in purine metabolism and signal transduction (kinases,
phosphatases) to gene expression regulators (Mony et al., 2014).
Identified genes at each step of the signaling pathway were
independently validated in cells naturally capable of stumpy
formation, confirming their role in density sensing in vivo. The
putative RNA-binding protein, RBP7, was required for normal
quorum sensing and promoted cell-cycle arrest and transmission
competencewhen overexpressed. Thus, quorum sensing signaling
in trypanosomes shares similarities to fundamental quiescence
pathways in eukaryotic cells, its components providing targets
for quorum-sensing interference-based therapeutics (Mony et al.,
2014).
While a direct role for cAMP in the initiation of trypanosome
differentiation events has thus become more doubtful, the role
and importance of cAMP in flagellar motility and signaling
is increasingly being dissected, with interesting findings. For
example it is commonly believed that the flagellum, as an
important host-parasite interface, has essential sensory functions
(Tetley and Vickerman, 1985; Rotureau et al., 2009). For example
in Chlamydomonas reinhardtii, the triggering of zygote formation
is initiated by cAMP signaling in response to flagellum adhesion
in gametes (Pan and Snell, 2000). Recently, it has been shown
that cAMP regulates social motility in procyclic T. brucei, with
social motility absent when TbrPDEB1 was inhibited by CpdA
or knocked down with RNAi. The reduction in PDEB activity
appeared to disrupt the generation of an extracellular signal
necessary for the behavior, as the social motility was completely
restored in mixed TbrPDEB1 knockdown and wild-type cells
(Oberholzer et al., 2015). This is similar to social motility
observation in D. discoideum where cAMP signaling is critical
for surface motility (Firtel and Meili, 2000). It is believed that
the social motility exhibited by the procyclic forms is essential
for their migration from the tsetse midgut to the insect’s salivary
gland, which allows it to complete it life cycle.
In BSFs of T. brucei, the most unambiguous role of cAMP is
in cytokinesis, as either the knockdown of ACs (Salmon et al.,
2012a), knockdown of TbrPDEB1 andB2 (Oberholzer et al., 2007)
or the pharmacological inhibition of these PDEs (de Koning et al.,
2012) all lead to severe defects in the cytokinesis phase of cell
division, resulting in misshaped cells with multiple nuclei and
kinetoplasts, that are ultimately non-viable.
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FIGURE 4 | Schematic diagram of cyclic nucleotide signaling in T. brucei, emphasizing the lack of investigative tools compared with the classical
mammalian model, where manipulation of receptors, G-proteins and cyclases are all possible. EPAC, exchange protein directly activated by cAMP.
Novel Downstream Effectors of cAMP in
Trypanosomes
Although cAMP has thus been implicated in important cellular
functions and behavior of trypanosomes, the effectors that
mediate this regulatory activity have been elusive. As noted
above, the only potential effector protein identified, PKA,
was not responsive to cAMP (Shalaby et al., 2001), and
it became clear that, instead of searching for mammalian
homologs, an unbiased approach to identify novel effector
proteins was required. Accordingly, Gould et al. (2013) generated
two CpdA-resistant lines. The first method involved exposing
wild-type T. b. brucei trypanosomes briefly to the mutagen
methyl methanesulfonate (MMS; Sigma), followed by culture in
increasing but sub-lethal concentrations of CpdA. The second
method employed the use of a genome-wide T. b. brucei RNAi
library (Alsford et al., 2011, 2012; Baker et al., 2011) to select for
resistance under CpdApressure. This screen revealed four distinct
genes that were knocked down, which were designated cAMP
Response Proteins (CARP1–4; Gould et al., 2013). Targeted RNAi
knockdown of these CARPs confirmed a significant increase
in resistance to CpdA and to elevated cellular cAMP levels,
confirming that they are genuine downstream effectors of cAMP
signaling. One of the genes knocked down in the CpdA-resistant
cultures was Tb427tmp.01.7890 (CARP1; Tb927.11.16210 in T.
b. brucei reference strain TREU 927), encoding a 705-amino-
acid protein containing two apparently intact and one partial
cyclic AMP binding-like domain, that is conserved in synteny
in each of the kinetoplastid genomes sequenced. Recently, the
homolog of CARP1 in T. cruzi TcCLB.508523.80 has been
reported to bind cyclic nucleotides, using cAMP and cGMP
displacement assays (Jäger et al., 2014), further validating the
role of CARP1 as a downstream cAMP signaling effector.
CARP2–4 are proteins of as yet unknown functions but some
of them have a probable flagellar localization, consistent with
a role in mediating or regulating a cAMP signal (Gould et al.,
2013).
Summary and Outlook
Differences in cAMP signaling between the mammalian system
and trypanosome are well documented, such as the many
and varied AC; no GPCRs or G-proteins; inactive PKA in T.
brucei; and as yet to be identified AC triggers (Figure 4).
However, from these differences opportunities may arise, as
the downstream effects as well as the cAMP modulating
receptor ligands appear to be unique to kinetoplastid parasites,
and may offer promising targets for therapeutic intervention.
The cAMP PDEs are already the focus of considerable drug
development programs at the interface of academic research and
pharmaceutical industry1,2.
1http://www.openlabfoundation.org/research/projects/details12.html
2http://www.tipharma.com/pharmaceutical-research-projects/neglected-
diseases/phosphodiesterase-inhibitors-for-neglected-parasitic-diseases-
pde4npd.html
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It is believed that as further studies of the downstream
effectors progress, many more similarities and/or differences
with mammalian regulatory pathways will come to the fore,
which will provide much needed insights into these important
biological processes in eukaryotic pathogens. This is even more
so as studies of cAMP signaling and its associated effect on
flagellar function and social motility is increasingly revealing
particularly important cellular activities of the trypanosome.
The importance of the flagellum to the trypanosome and
how it interacts with its environment cannot be overstated.
Thus, trypanosomal cAMP signaling, and the role of the
flagellum therein, offer a ready and important biological system
for much needed, innovative strategies for antiprotozoal drug
development.
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